Compare Stocks: SXTC, GELS, NCNA, and PULM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GELS Gelteq	$0.54 +4.3%	$0.60	$0.39 ▼ $2.01	$5.58M	-0.41	1.86 million shs	37,286 shs
NCNA NuCana	$1.06 -2.8%	$1.38	$0.95 ▼ $7.22	$4.54M	2.3	242,708 shs	70,229 shs
PULM Pulmatrix	$1.48 -5.7%	$1.55	$1.16 ▼ $5.50	$5.73M	1.93	47,074 shs	24,143 shs
SXTC China SXT Pharmaceuticals	$2.08 -13.7%	$3.37	$1.54 ▼ $83,758.80	$1.15M	1.86	880,428 shs	948,115 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GELS Gelteq	+4.30%	-0.59%	-39.59%	-6.42%	-57.19%
NCNA NuCana	-2.75%	-17.83%	-24.29%	-23.74%	-77.35%
PULM Pulmatrix	-5.73%	-7.44%	+6.47%	-14.45%	-69.61%
SXTC China SXT Pharmaceuticals	-13.69%	-17.46%	-6.73%	-98.94%	-99.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GELS Gelteq	$0.54 +4.3%	$0.60	$0.39 ▼ $2.01	$5.58M	-0.41	1.86 million shs	37,286 shs
NCNA NuCana	$1.06 -2.8%	$1.38	$0.95 ▼ $7.22	$4.54M	2.3	242,708 shs	70,229 shs
PULM Pulmatrix	$1.48 -5.7%	$1.55	$1.16 ▼ $5.50	$5.73M	1.93	47,074 shs	24,143 shs
SXTC China SXT Pharmaceuticals	$2.08 -13.7%	$3.37	$1.54 ▼ $83,758.80	$1.15M	1.86	880,428 shs	948,115 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GELS Gelteq	+4.30%	-0.59%	-39.59%	-6.42%	-57.19%
NCNA NuCana	-2.75%	-17.83%	-24.29%	-23.74%	-77.35%
PULM Pulmatrix	-5.73%	-7.44%	+6.47%	-14.45%	-69.61%
SXTC China SXT Pharmaceuticals	-13.69%	-17.46%	-6.73%	-98.94%	-99.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GELS Gelteq	1.00	Sell	N/A	N/A
NCNA NuCana	1.00	Sell	N/A	N/A
PULM Pulmatrix	1.00	Sell	N/A	N/A
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, GELS, NCNA, and PULM Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/22/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/31/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/14/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/30/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GELS Gelteq	$110K	52.94	N/A	N/A	$1.08 per share	0.50
NCNA NuCana	N/A	N/A	N/A	N/A	$7.71 per share	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	$2.45 per share	N/A
SXTC China SXT Pharmaceuticals	$1.14M	0.87	N/A	N/A	$2,468.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GELS Gelteq	-$4.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	11/12/2026 (Estimated)
PULM Pulmatrix	-$5.16M	-$1.10	N/A	N/A	N/A	N/A	-125.65%	-95.19%	11/5/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$6.20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SXTC, GELS, NCNA, and PULM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A
8/13/2026	Q2 2026	PULM Pulmatrix	-$2.00	-$0.29	+$1.71	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GELS Gelteq	N/A	N/A	N/A
NCNA NuCana	N/A	4.73	4.73
PULM Pulmatrix	N/A	4.70	4.70
SXTC China SXT Pharmaceuticals	0.02	7.94	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GELS Gelteq	N/A
NCNA NuCana	44.00%
PULM Pulmatrix	11.84%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
GELS Gelteq	N/A
NCNA NuCana	31.20%
PULM Pulmatrix	0.62%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GELS Gelteq	8	10.71 million	N/A	N/A
NCNA NuCana	11	4.16 million	2.86 million	Not Optionable
PULM Pulmatrix	2	3.65 million	3.63 million	Not Optionable
SXTC China SXT Pharmaceuticals	56	478,000	459,000	Not Optionable

SXTC, GELS, NCNA, and PULM Headlines

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

September 26, 2026 | americanbankingnews.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

August 5, 2026 | globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

July 24, 2026 | globenewswire.com

China SXT Pharmaceuticals Raises $9 Million in Registered Direct Offering

July 24, 2026 | tipranks.com

China SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional Investors

July 23, 2026 | quiverquant.comQ

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

July 23, 2026 | globenewswire.com

China SXT Pharmaceuticals Inc. Cl A

July 14, 2026 | barrons.com

China SXT Pharmaceuticals shares surge over 25% after hours: Here's why

June 2, 2026 | msn.com

China SXT Pharmaceuticals Launches $100 Million ATM Equity Program with Univest Securities

June 1, 2026 | tipranks.com

China SXT Pharmaceuticals Raises $3.5 Million in Offshore Private Placement

May 11, 2026 | theglobeandmail.com

China Sxt Pharmaceuticals, Inc. Class A

April 7, 2026 | edition.cnn.com

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

March 23, 2026 | globenewswire.com

This nano-cap pharma stock crashed 30% today – what triggered the sell-off?

January 30, 2026 | msn.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

January 30, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

January 15, 2026 | finance.yahoo.com

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

January 13, 2026 | globenewswire.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 8.81%

January 11, 2026 | aaii.comA

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

January 9, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND ...

January 8, 2026 | markets.businessinsider.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Up 6.88%

January 3, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SXTC, GELS, NCNA, and PULM Company Descriptions

Gelteq NASDAQ:GELS

$0.54 +0.02 (+4.30%)

Closing price 10/5/2026 03:59 PM Eastern

Extended Trading

$0.53 -0.02 (-3.26%)

As of 10/5/2026 07:56 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

NuCana NASDAQ:NCNA

$1.06 -0.03 (-2.75%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.03 -0.03 (-2.92%)

As of 10/5/2026 07:49 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Pulmatrix NASDAQ:PULM

$1.48 -0.09 (-5.73%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.04 (+3.04%)

As of 10/5/2026 07:50 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.08 -0.33 (-13.69%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$2.03 -0.05 (-2.21%)

As of 10/5/2026 07:57 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, GELS, NCNA, and PULM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, GELS, NCNA, and PULM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, GELS, NCNA, and PULM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SXTC, GELS, NCNA, and PULM Company Descriptions

Gelteq NASDAQ:GELS

NuCana NASDAQ:NCNA

Pulmatrix NASDAQ:PULM

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, GELS, NCNA, and PULM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, GELS, NCNA, and PULM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, GELS, NCNA, and PULM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SXTC, GELS, NCNA, and PULM Company Descriptions

Gelteq NASDAQ:GELS

NuCana NASDAQ:NCNA

Pulmatrix NASDAQ:PULM

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools